Compare Amphastar Pharmaceuticals Inc (AMPH) vs Dicks Sporting Goods Inc (DKS) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

DKS trades at $217.98, up 0.3% on the day, with a bearish technical signal but strong fundamentals including a 6% comps growth in Q1 2026 and three consecutive quarterly earnings beats. Recent developments include the launch of the ScoreCard+ loyalty program and a partnership with Lids to expand fan merchandise in over 100 stores by late summer 2026. The stock shows robust profitability with a 20.9% ROE and a 4.71% net income margin, supported by $1.17B net income in 2025.

The outlook is positive with a consensus price target of $261, representing 19.7% upside, and no sell ratings among 64 analysts. Key risks include ongoing shareholder litigation over fiduciary duties and competitive pressures in sporting goods retail. The stock presents a growth opportunity driven by strategic expansions and consistent earnings performance, though investors should monitor legal developments and market share sustainability.